Next-Generation Therapeutics: Bridging Antibody Discovery and mRNA Technologies

Dr Christoffer Norn is Co-Founder and CEO of Skape Bio, a biotechnology company harnessing AI-powered protein design and synthetic biology to develop next-generation therapeutics targeting integral membrane proteins. The company’s platform combines advanced computational protein design with high-throughput in-cell screening in human cells, enabling discovery of novel functional modulators, including previously inaccessible GPCR targets. Skape Bio develops de novo minibinders with strong developability and optimized pharmacological properties for applications across oncology, inflammation, metabolic disease, and neurology. The company is a spinout of the “Modulate” collaboration between the BioInnovation Institute and the University of Washington’s Institute for Protein Design led by David Baker

Dr Luo leads product strategy and development for protein expression and antibody discovery platforms supporting biologics research and drug discovery. She focuses on building integrated solutions that enable high-throughput protein production and accelerate biologics discovery workflows.
Dr Luo holds a PhD in Materials Science and Engineering from Johns Hopkins University and has over eight years of experience in product management within the life sciences and biotechnology industry, spanning molecular biology tools, gene products, chemicals, and protein expression systems.

Linda Tchatchouang Nobana supports pharmaceutical and biotech partners across Europe in antibody drug discovery (ADD) and AI-driven drug discovery (AIDD). With over 10 years of experience, she works closely with scientists to understand their challenges and connect them with the right tools and expertise to accelerate research and development.
She is passionate about enabling the transition from early-stage ideas to impactful projects, acting as a bridge between innovation and execution to ensure scientific progress is translated into real-world outcomes.

Dr Naylor leads the European scientific consulting team supporting antibody discovery, mRNA, cell and gene therapy, and advanced biologics development. In her current role, she works closely with partners to design and deliver integrated solutions across therapeutic antibody discovery, mRNA technologies, and gene editing workflows, helping bridge complex research needs with solution application.
Dr Naylor holds a PhD in Translational Medicine from The University of Manchester and a BSc in Biochemistry from the University of Warwick.

Dr Campo supports mRNA technologies and the CRISPR portfolio. In her current role, she works closely with customers across Europe, providing technical expertise in mRNA workflows and supporting the application of advanced gene and cell engineering solutions to bridge research and translational development.
Dr Campo holds a PhD in Neuroimmunology from Charité – Universitätsmedizin Berlin, with extensive research experience in neurobiology and stem cell–immune interactions.

Dr. Siow is a Field Application Scientist at GenScript, where he supports customers with in-house CHO expression, supporting the full molecular biology portfolio, CRISPR-based genome editing, and viral vectors. In his current role, he provides technical support across the European region, helping bridge early-stage research with applied development.

Before joining GenScript, Dr Siow worked at Revvity as a Technical Account Manager, supporting customers in Germany and Switzerland with complex experimental workflows and contributing to regional business growth.
Dr Siow holds a Bachelor’s and Master’s degree in Cancer Biology from Taiwan and a PhD in Pharmaceutical Biology from the University of Munich in Germany.

Lasse Møller Blaabjerg is a Scientist in Discovery Data Science at Genmab, where he focuses on applying computational and machine learning methods to antibody drug design. He obtained his PhD from the University of Copenhagen in the lab of Kresten Lindorff-Larsen.